Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | CCR6 | P51684 | 2/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | CCR9 | P51686 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19232104 | 0.86 | KDM4E (0.40) | KDM4EALDH1A1HPGDL3MBTL1HTT | |
| SCHEMBL19464705 | 0.86 | KDM4E (0.41) | KDM4EALDH1A1HPGDL3MBTL1HTT | |
| SCHEMBL21166257 | 0.81 | KDM4E (0.49) | KDM4EALDH1A1HPGDL3MBTL1HTT | |
| SCHEMBL1243269 | 0.81 | ALDH1A1 (0.46) | KDM4EALDH1A1HPGDL3MBTL1HTT | |
| SCHEMBL19464700 | 0.80 | KDM4E (0.39) | KDM4EALDH1A1HPGDL3MBTL1HTT | |
| SCHEMBL29858989 | 0.78 | ALDH1A1 (0.43) | KDM4EALDH1A1HPGDL3MBTL1HTT | |
| SCHEMBL18397439 | 0.78 | ALDH1A1 (0.43) | KDM4EALDH1A1HPGDL3MBTL1HTT | |
| SCHEMBL20304972 | 0.78 | CHRNA7 (0.44) | KDM4EALDH1A1HPGDL3MBTL1HTT | |
| SCHEMBL19464607 | 0.76 | KDM4E (0.47) | KDM4EALDH1A1HPGDL3MBTL1HTT | |
| SCHEMBL12064460 | 0.74 | CLK4 (0.35) | CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11242332-B2 | Method for producing benzimidazole derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-02-08 | — | — | US | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10736883-B2 | Triazole furan compounds as agonists of the APJ receptor | AMGEN INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20200071295-A1 | METHOD FOR PRODUCING BENZIMIDAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2020-03-05 | — | — | US | disclosed |
| US-20190275008-A1 | TRIAZOLE FURAN COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2019-09-12 | — | — | US | disclosed |
| US-10399933-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| US-10167254-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180094010-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | NEWGEN THERAPEUTICS INC (US) | 2018-04-05 | — | — | US | disclosed |
| US-20180072660-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-15 | — | — | US | disclosed |
| US-9790169-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170231999-A1 | IDO INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10167254-B2 | IDO inhibitors | IDO1, IDO2, INMT | KDM4E 272/4885ALDH1A1 707/4885HPGD 129/4885 |
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | KDM4E 1648/4885ALDH1A1 1320/4885HPGD 1676/4885 |
| US-20170231999-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | KDM4E 272/4885ALDH1A1 707/4885HPGD 129/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | KDM4E 1648/4885ALDH1A1 1320/4885HPGD 1676/4885 |
| US-20190275008-A1 | TRIAZOLE FURAN COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, APLNR | KDM4E 4612/4885ALDH1A1 1700/4885HPGD 1202/4885 |
| US-20180094010-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | PARP1, PARP2, PARP11 | KDM4E 2241/4885ALDH1A1 1069/4885HPGD 694/4885 |
| US-11242332-B2 | Method for producing benzimidazole derivative | CYP3A4, CYP3A5, CYP3A43 | KDM4E 1092/4885ALDH1A1 268/4885HPGD 174/4885 |
| US-20180072660-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | KDM4E 375/4885ALDH1A1 263/4885HPGD 65/4885 |
| US-10399933-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | IDO1, IDO2, INMT | KDM4E 375/4885ALDH1A1 263/4885HPGD 65/4885 |
| US-10736883-B2 | Triazole furan compounds as agonists of the APJ receptor | TBXA2R, AGTR1, APLNR | KDM4E 4612/4885ALDH1A1 1700/4885HPGD 1202/4885 |
| US-20200071295-A1 | METHOD FOR PRODUCING BENZIMIDAZOLE DERIVATIVE | CYP3A4, CYP3A5, CYP3A43 | KDM4E 1092/4885ALDH1A1 268/4885HPGD 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.